Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $3.7 million.

  • Agios Pharmaceuticals' Change in Accured Expenses rose 156.13% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 38.80%. This contributed to the annual value of $3.7 million for FY2024, which is 71.18% down from last year.
  • Agios Pharmaceuticals' Change in Accured Expenses amounted to $3.7 million in FY2024, which was down 71.18% from $12.8 million recorded in FY2023.
  • Agios Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $12.8 million during FY2023, with a 5-year trough of $66,000 in FY2021.
  • For the 3-year period, Agios Pharmaceuticals' Change in Accured Expenses averaged around $6.5 million, with its median value being $3.7 million (2024).
  • Per our database at Business Quant, Agios Pharmaceuticals' Change in Accured Expenses tumbled by 99.02% in 2021 and then skyrocketed by 4,450.00% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $6.8 million in 2020, then crashed by 99.02% to $66,000 in 2021, then spiked by 4,450.00% to $3.0 million in 2022, then spiked by 326.81% to $12.8 million in 2023, then plummeted by 71.18% to $3.7 million in 2024.